Is Egrifta (Tesamorelin) Legal in Oregon?
HealthRX.com
Egrifta is an FDA-approved prescription drug in Oregon
Key numbers
- 1.4 mgEgrifta SV dose, once daily; Egrifta WR is 1.28 mg once daily and the two are not substitutableSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 3 SDSIGF-1 level above which the label says to consider stopping treatment, especially if fat loss is weakSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 25%Tesamorelin patients with injection-site reactions in first 26 weeks, versus 14% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 5%Tesamorelin patients reaching HbA1c 6.5% or higher by week 26 in the trialsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Tesamorelin
At a glance
- Federal status / FDA-approved prescription drug, first approved November 10, 2010 (BLA 022505) [1]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [3]
- Current products / Egrifta SV 1.4 mg once daily and Egrifta WR 1.28 mg once daily; the formulations are not substitutable [3][4]
- Oregon pharmacy law / ORS chapter 689 covers pharmacists, drug outlets and drug sales [2]
- Compounding / FDA places tesamorelin in no category on its compounding lists [5][6][7]
- Sport / Prohibited at all times under WADA category S2.2.4 [8]
What the FDA approval covers
Egrifta is indicated for one thing: reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The label adds three limits: long-term cardiovascular safety has not been established, the drug is not indicated for weight loss management because its effect on weight is neutral, and there are no data showing improved adherence to antiretroviral therapy [3].
Tesamorelin is a synthetic analog of human growth hormone-releasing factor, a peptide rather than growth hormone itself. It binds GRF receptors on pituitary somatotroph cells and prompts the pituitary to release the body's own growth hormone, which in turn raises IGF-1 and IGFBP-3 [3].
What Oregon law says about tesamorelin
Oregon's pharmacy statutes are compiled in ORS chapter 689, titled Pharmacists; Drug Outlets; Drug Sales. The chapter covers licensing of pharmacists and drug outlets, labeling and prescription records, and includes a section titled Prohibited practices [2]. None of the section titles refers to tesamorelin [2].
Egrifta itself is a prescription product, not sold over the counter [1].
Questions worth asking
What about compounded tesamorelin?
FDA keeps lists of bulk drug substances for state-licensed pharmacies and for outsourcing facilities. Tesamorelin appears in no category on either list, and it does not appear on FDA's page of bulk substances that may present significant safety risks (content dated April 22, 2026), so the agency has made no category-based statement about compounding it [5][6][7]. Tesamorelin is also not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 as Federal Register document 2026-22192 [9][10].
Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [10]. Tesamorelin is a component of an FDA-approved drug, Egrifta [1].
Is tesamorelin prohibited in sport?
WADA's Prohibited List names tesamorelin in S2.2.4 among growth hormone releasing factors, prohibited at all times, in and out of competition [8]. It stays on the 2027 Prohibited List [11].
What does the label say to watch for?
The Egrifta SV and Egrifta WR labels contraindicate tesamorelin in people with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [3][4].
The label says to monitor IGF-1 and to consider stopping if levels stay high (for example above 3 SDS), particularly when the fat-loss response is not robust, and to evaluate glucose before and during treatment [3]. In the trials, 5% of tesamorelin-treated patients and 1% of placebo patients reached an HbA1c of 6.5% or higher by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [3]. Injection-site reactions occurred in 25% of tesamorelin patients versus 14% on placebo during the first 26 weeks [3].
Frequently asked questions
Is Egrifta (tesamorelin) legal in Oregon?
Is compounded tesamorelin legal in Oregon?
What is tesamorelin approved to treat?
What dose of Egrifta is approved?
Is tesamorelin banned in sport?
References
Show all 11 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- Oregon Revised Statutes.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Official web page.
- Official web page.
- World Anti-Doping Agency.